Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Genetics and Molecular Research

Volumn 10, Issue 4, 2011, Pages 3609-3619

  Gu, Y ^a   Zhou, X ^a   Zhang, S L ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial cancer; Meta analysis; P53 gene; Polymorphism; Susceptibility

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ALLELE; ARTICLE; ASIAN; CANCER PATIENT; CANCER RISK; CAUCASIAN; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; META ANALYSIS (TOPIC); POPULATION GENETICS; POPULATION RESEARCH; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; ENDOMETRIUM TUMOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PUBLISHING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

CODON; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINEAR MODELS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865627991     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2011.October.31.11     Document Type: Article

References (34)

1. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, et al. (2004). P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur. J. Cancer Prev. 13: 277-280.
2. Ashton KA, Proietto A, Otton G, Symonds I, et al. (2009). Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol. Oncol. 113: 109-114.
3. Berchuck A, Kohler MF, Marks JR, Wiseman R, et al. (1994). The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 170: 246-252.
4. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, et al. (1997). Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer 75: 1385-1388.
5. Fan R, Wu MT, Miller D, Wain JC, et al. (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9: 1037-1042.
6. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR and Atash-Afza A (2010). Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet. Cytogenet. 196: 167-170.
7. Grochola LF, Zeron-Medina J, Meriaux S and Bond GL (2010). Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb. Perspect. Biol. 2: a001032.
8. Harris CC and Hollstein M (1993). Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329: 1318-1327.
9. Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558.
10. Ioannidis JP, Ntzani EE, Trikalinos TA and Contopoulos-Ioannidis DG (2001). Replication validity of genetic association studies. Nat. Genet. 29: 306-309.
11. Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
12. Koushik A, Platt RW and Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol. Biomarkers Prev. 13: 11-22.
13. Lax SF (2004). Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 444: 213-223.
14. Munafo M (2004). Replication validity of genetic association studies of smoking behavior: what can meta-analytic techniques offer? Nicotine Tob. Res. 6: 381-382.
15. Ng TT, McGory ML, Ko CY and Maggard MA (2006). Meta-analysis in surgery: methods and limitations. Arch. Surg. 141: 1125-1130.
16. Niwa Y, Hirose K, Matsuo K, Tajima K, et al. (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 219: 183-190.
17. Nunobiki O, Ueda M, Yamamoto M, Toji E, et al. (2009). Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum. Cell 22: 101-106.
18. Ozalp S, Yalcin OT, Tanir HM, Kabukcuoglu S, et al. (2003). p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 24: 275-278.
19. Pecorelli S, Favalli G, Zigliani L and Odicino F (2003). Cancer in women. Int. J. Gynaecol. Obstet. 82: 369-379.
20. Peller S, Halperin R, Schneider D, Kopilova Y, et al. (1999). Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6: 193-197.
21. Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
22. Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, et al. (1992). p53 gene mutations in human endometrial carcinoma. Mol. Carcinog. 5: 250-253.
23. Roh JW, Kim JW, Park NH, Song YS, et al. (2004). p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol. 93: 499-505.
24. Sherman ME (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13: 295-308.
25. Soliman PT, Oh JC, Schmeler KM, Sun CC, et al. (2005). Risk factors for young premenopausal women with endometrial cancer. Obstet. Gynecol. 105: 575-580.
26. Ueda M, Terai Y, Kanda K, Kanemura M, et al. (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol. Oncol. 100: 173-178.
27. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835.
28. Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52.
29. Whibley C, Pharoah PD and Hollstein M (2009). p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9: 95-107.
30. Yang HP, Gonzalez BJ, Li Q, Platz EA, et al. (2010). Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis 31: 827-833.
31. Ye S (2000). Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19: 623-629.
32. Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137.
33. Zubor P, Stanclova A, Kajo K, Hatok J, et al. (2009). The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology 76: 173-183.
34. Zucchetto A, Serraino D, Polesel J, Negri E, et al. (2009). Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur. J. Cancer Prev. 18: 316-321.